Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants

Rosemary Hoyt, David Ritchie, Andrew W Roberts, Lachlan MacGregor, David John Curtis, Jeffrey Szer, Andrew P Grigg

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

The utility of GVHD prophylaxis with cyclosporin, MTX and prednisolone (CSA/MTX/Pred) in allogeneic PBPC transplants is not well described although there are published data using this combination after bone marrow transplants. The effectiveness of this regimen on the prevention of GVHD was assessed in 107 consecutive sibling and less-than-ideal donor transplant recipients over a 5-year period and compared to that observed in 65 patients receiving standard CSA and short-course MTX without prednisolone. Oral prednisolone was commenced on day +14 at 0.5mg/kg per day, increased to 1mg/kg per day on day +21 to day +34 then gradually tapered and ceased by day +100. The cumulative incidence of acute GVHD (grades II-IV) to day 100 in those receiving prednisolone prophylaxis was lower (52 versus 76 , P
Original languageEnglish
Pages (from-to)651 - 658
Number of pages8
JournalBone Marrow Transplantation
Volume41
Issue number7
DOIs
Publication statusPublished - 2008

Cite this